Clinical Trial: 19062

Trial Status: Open
Disease Type: Lymphoma
Trial ID 19062
Sponsor ID Epizyme, Inc.

Phase 3 Double-Blind, Active Controlled, 3-Stage Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma.

Principal Investigator
Mitul Gandhi, MD
4 Locations


Fairfax Office

Gainesville Office

Arlington Office

Alexandria Office

Learn More About This Trial

Other Relevant Trials
Trial ID DR-01-ONC-001
Sponsor ID Dren Bio

A Multicenter, Open-Label, First-in-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Trial ID ADCT-402-105
Sponsor ID LOTIS-7

A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

Principal Investigator
Mitul Gandhi, MD
1 Location